Results 231 to 240 of about 3,155,563 (287)

Clinical Efficacy of Local Injection of Compound Betamethasone Versus Triamcinolone Acetonide in the Treatment of Hypertrophic Scars: A Retrospective Analysis of 126 Patients. [PDF]

J Cosmet Dermatol
Mao J, He M.
europepmc   +1 more source

Is there a role for the no observed adverse effect level in safety pharmacology?

Journal of Pharmacological and Toxicological Methods, 2020
In nonclinical toxicology the highest dose or exposure without test article-related adverse effects, known as the No Observed Adverse Effect Level (NOAEL), is a variable that may be determined. In safety pharmacology the vast majority of the endpoints measured are quantitative numeric functional endpoints such as changes in heart rate, blood pressure ...
Mow, Tomas, Andersen, Ninette K., Dragsted, Nils, Lassen, Anders B., Laursen, Morten, Bass, Alan S., Valentin, Jean Pierre, Markgraf, Carrie, Authier, Simon, Baird, Theodore J., Bhatt, Siddhartha, Traebert, Martin, Leishman, Derek J., Jones, David, Curtis, Michael J.   +14 more
openaire   +4 more sources

Integrated In Silico Models for the Prediction of No-Observed-(Adverse)-Effect Levels and Lowest-Observed-(Adverse)-Effect Levels in Rats for Sub-chronic Repeated-Dose Toxicity

Chemical Research in Toxicology, 2020
Repeated-dose toxicity (RDT) is a critical endpoint for hazard characterization of chemicals and is assessed to derive safe levels of exposure for human health. Here we present the first attempt to model simultaneously no-observed-(adverse)-effect level (NO(A)EL) and lowest-observed-(adverse)-effect level (LO(A)EL). Classification and regression models
Domenico Gadaleta, Marco Marzo, Andrey Toropov, Alla Toropova, Giovanna J. Lavado, Sylvia E. Escher, Jean Lou C. M. Dorne, Emilio Benfenati   +7 more
openaire   +3 more sources

An updated evaluation of reported no-observed adverse effect levels for chrysotile asbestos for lung cancer and mesothelioma

Critical Reviews in Toxicology, 2016
Although consumption of chrysotile asbestos has decreased since the 1970s, the latency period of asbestos-related cancers is thought to be at least 20-30 years, and therefore the potential health risks associated with historical exposures is still actively researched.
Jennifer S, Pierce, Peter S, Ruestow, Brent L, Finley   +2 more
openaire   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Statistical Uncertainty in the No-Observed-Adverse-Effect Level

Toxicological Sciences, 1989
The no-observed-adverse-effect level (NOAEL) is a dose value that U.S. EPA reduces by uncertainty factors (UF) and modifying factors (MF) to obtain a reference dose (RfD) for input to regulatory decision making. Whether the true added risk at the NOAEL is below an acceptable level, however, is a source of statistical uncertainty itself.
K G, Brown, L S, Erdreich
openaire   +2 more sources